Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Regen Biopharma, Inc. develops regenerative and immunotherapy treatments, focusing on cellular therapies, gene silencing, and immune modulation. Its core products include HemaXellerate for bone marrow repair and various cancer immunotherapies targeting NR2F6. The company licenses its innovative biotech IP, collaborates with partners, and advances preclinical and clinical research to develop novel biologics for rare diseases and cancer.
This description was generated via AI from an annual report. Updated about 1 year ago.